Equities

Icecure Medical Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
ICCM:NAQ

Icecure Medical Ltd

Actions
Health CareMedical Equipment and Services
  • Price (USD)0.590
  • Today's Change0.039 / 7.04%
  • Shares traded133.16k
  • 1 Year change-54.26%
  • Beta2.2563
Data delayed at least 15 minutes, as of Feb 06 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.

  • Revenue in USD (TTM)2.98m
  • Net income in USD-15.29m
  • Incorporated2006
  • Employees64.00
  • Location
    Icecure Medical Ltd7 Ha'eshel St.,PO Box 3163CAESAREA 3079504IsraelISR
  • Phone+972 46230333
  • Fax+972 46230222
  • Websitehttps://icecure-medical.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Baird Medical Investment Holdings Ltd31.86m-3.12m33.80m143.00--0.6867--1.06-0.1128-0.11281.221.340.45523.270.8459222,797.30-4.48---7.64--86.94---9.84--1.67-0.3230.3856--17.74--18.57------
Modular Medical Inc0.00-24.22m33.94m54.00--3.05-----0.5081-0.50810.000.14340.00----0.00-222.79-171.42-294.38-207.14------------0.00-------7.75--57.07--
Precipio Inc22.80m-1.25m35.15m54.00--2.55145.231.54-0.835-0.83514.637.881.2018.2615.31422,222.20-6.58-38.01-8.60-46.9844.8233.80-5.50-71.341.10-24.190.074--21.9542.7426.70--32.31--
Ekso Bionics Holdings Inc14.75m-10.66m35.32m61.00--2.82--2.39-5.70-5.707.253.690.57991.362.27241,786.90-41.02-41.01-60.62-52.9053.4852.89-70.74-97.041.09--0.3055---1.945.1925.45---9.22--
TELA Bio Inc77.06m-39.00m35.49m209.00--21.01--0.4606-0.8863-0.88631.750.03861.342.016.85368,684.20-68.06-51.29-96.57-60.7067.2366.26-50.61-88.022.62-7.250.9638--18.5635.0218.91---18.18--
RenovoRx Inc928.00k-11.11m36.28m10.00--4.49--39.10-0.4375-0.43750.03120.22040.0874----92,800.00-104.58-121.57-126.33-166.5067.78---1,196.66-90,830.235.68--0.00------13.86------
Neuroone Medical Technologies Corp12.10m-3.61m39.35m18.00--5.52--3.25-0.0784-0.07840.30120.14141.501.6316.79672,094.40-44.63-113.64-61.95-152.0867.3060.94-29.80-223.443.47--0.1519--250.3544.4170.73---7.76--
Icecure Medical Ltd2.98m-15.29m40.69m64.00--4.37--13.68-0.2586-0.25860.05010.13490.1960.823524.3946,484.38-100.74-61.14-155.92-77.1135.0650.17-513.95-343.951.90--0.00--1.9215.35-4.55---6.51--
EUDA Health Holdings Ltd5.16m-2.06m41.97m117.0071.84----8.130.01550.08760.1483-0.09982.49--17.1044,104.96-100.77------22.39---40.53--0.2084-46.54----8.22---108.62------
Cytosorbents Corp34.35m-10.59m42.20m149.00--4.68--1.23-0.19-0.190.560.14360.73442.184.89230,553.30-22.63-34.58-28.22-41.8077.0270.00-30.81-62.081.71--0.6176--14.517.3729.16---15.13--
Precision Optics Corporation Inc21.58m-6.11m43.54m90.00--3.98--2.02-0.8505-0.85053.011.421.095.005.90239,722.70-30.82-13.63-45.79-19.5114.9929.56-28.30-11.580.785-28.850.1375---0.068513.98-95.85--7.81--
electroCore, Inc.29.84m-14.16m43.58m73.00------1.46-1.70-1.703.59-0.14051.412.6329.39408,698.60-66.70-65.38-126.40-87.8786.0480.72-47.46-159.341.33--1.20--57.0960.1536.89------
Neuraxis Inc3.36m-8.37m46.34m21.00--18.85--13.78-1.02-1.020.40590.23110.97187.9441.74160,111.00-217.93---1,360.57--84.34---224.24--1.55-97.220.0789--9.18--42.21------
Spectral AI Inc23.17m-16.37m46.65m78.00------2.01-0.7206-0.72060.9706-0.3011.7228.4112.12297,025.70-121.66------45.01---70.64--0.8252-11.99----63.83--26.56------
Sharps Technology Inc2.51m-104.37m47.84m5.00--0.1052--19.05-690.20-690.200.395715.680.0111.81--502,354.00-45.86-86.10-47.44-125.430.1489---4,155.30--3.67--0.0173------5.54--65.50--
Data as of Feb 06 2026. Currency figures normalised to Icecure Medical Ltd's reporting currency: US Dollar USD

Institutional shareholders

0.59%Per cent of shares held by top holders
HolderShares% Held
Concurrent Investment Advisors LLCas of 31 Dec 202578.29k0.11%
UBS Securities LLCas of 31 Dec 202575.95k0.11%
Two Sigma Securities LLCas of 30 Sep 202550.17k0.07%
HRT Financial LPas of 30 Sep 202546.70k0.07%
Geode Capital Management LLCas of 30 Sep 202540.45k0.06%
Citadel Securities LLCas of 30 Sep 202537.17k0.05%
LPL Financial LLCas of 30 Sep 202523.38k0.03%
Gunderson Capital Management, Inc.as of 31 Dec 202520.00k0.03%
UBS Switzerland AG (Investment Management)as of 31 Dec 202516.22k0.02%
Foundations Investment Advisors LLCas of 30 Sep 202515.00k0.02%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.